Compare INUV & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INUV | ALLR |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 26.1M |
| IPO Year | 1996 | 2021 |
| Metric | INUV | ALLR |
|---|---|---|
| Price | $1.60 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $11.00 | $9.75 |
| AVG Volume (30 Days) | 184.2K | ★ 263.2K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $86,209,305.00 | $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.89 | N/A |
| P/E Ratio | $12.85 | ★ N/A |
| Revenue Growth | ★ 2.88 | N/A |
| 52 Week Low | $0.36 | $0.77 |
| 52 Week High | $6.27 | $2.35 |
| Indicator | INUV | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 60.41 |
| Support Level | $1.31 | $1.34 |
| Resistance Level | $2.01 | $1.79 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 41.09 | 64.06 |
Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.